This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
WASHINGTON, February 18, 2025 PharmD Live , an innovative pharmacist-led virtual care solution powered by AI-driven algorithms, announces the release of its recent whitepaper, Maximizing Shared Savings for Payviders: ACOs, IDNs, At-Risk Provider Groups and Clinics. Download the whitepaper here.
Spain’s Hospital Universitario 12 de Octubre researchers, along with the Josep Carreras Leukaemia Research Institute, have developed a new cell therapy based on STAb cells to treat a type of leukaemia. The post Hospital Universitario and Josep Carreras develop cell therapy for leukaemia appeared first on Pharmaceutical Technology.
The overall aim of the alliance – which will see Healthware work alongside the NCI’s Pascale Hospital – is to develop digital health tools that will deliver “more precise and accessible treatments to patients”, said the partners in a statement.
Malaysia: Health WhitePaper The Health WhitePaper , which was first tabled in the Parliament on 14 June 2023, is a comprehensive proposal to revamp the country's healthcare system for a higher quality, more sustainable and resilient health system in stages over a 15-year period.
In December last year, the first centre in Japan received authorisation to administer the therapy, while six regional hospitals are currently approved to offer this treatment. The delivery of the product is anticipated to begin early next year.
In this whitepaper, we outline three approaches for pharma companies to reach healthcare professionals (HCPs) in this changing landscape. coh-slider-nav-bottom","rows":0},"md":{"slidesToShow":3,"rows":0},"ps":{"slidesToShow":1,"rows":0}}, "rows" : 0, "slide" : ".coh-slider-item",
Preamble Why this WhitePaper? A whitepaper (sometimes called as whitepaper) is an information document issued by an organization to highlight the solution to a problem the functionality of a solution, good, or service. In this whitepaper, we will explore the key principles of GMaP in the pharmaceutical industry.
In this issue: Payers confess: Patients lose from copay accumulators Humana joins the Express Scripts GPO Hospitals vs. PBMs over specialty pharmacy white bagging Let’s all follow the Buy-and-Bill Dollar! Re: UnitedHealthcare Coverage Policies , American Hospital Association. The paper also shows a non-340B example.).
The Centers for Disease Control and Prevention (CDC) estimates that on any given day, 1 in 31 hospital patients and 1 in 43 nursing home residents has an infection as a result of their care. An estimated 72,000 patients will die each year. HAIs can often be prevented through careful monitoring and safety protocols overseen by IPs.
The amount paid back depends on spending in different categories, with percentage shares set out for retail pharmacies, hospitals, local health authority facilities as well as retail pharmacies when they are acting on behalf of local health authorities. The Italian industry makes regular paybacks when spending ceilings are breached.
As paediatric hospital wings are flooded with an unprecedented number of respiratory syncytial virus (RSV) cases , healthcare workers have been overwhelmed by an unusually early peak of the RSV season. In the Northern hemisphere, RSV season occurs from autumn to the end of spring and tends to coincide with influenza season.
Both the Administration and Congress have given significant attention to this pervasive issue, as recognized in the recent whitepaper published by the U.S. The policy recommendations therein aim to help prevent and mitigate shortages, ensuring that patients have access to the quality medicines they need when they need them.
Referring to generics provider Civica , a non-profit created by hospitals and philanthropies that partners with U.S. The center recently issued a whitepaper on the topic. When it comes to generic drugs in particular, prices “come down too much,” he said. “We We need to really look at … price point.”
Department of Health and Human Services (HHS) recently published a WhitePaper on Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States —with input from several HHS stakeholders, including FDA, CMS, and the Administration for Strategic Preparedness and Response. By Kalie E.
Effective health care services encompass a broad spectrum of services including primary care, specialty care, hospital care, long-term care, palliative care, behavioral health care, rehabilitative services, health promotion, disease prevention, and public health.31 nmqf.org/s/Disparities-and-Value-Assesssment-White-Paper.pdf 17 Stoumpos, A.,
Of these three, the highest costs for US hospitals are from NTM i nfections at $1.53bn. Identifying the biggest risks for NTM infections in hospitals All healthcare facilities should have a water safety plan to control the opportunities and conditions to prevent bacteria growing and spreading. You can’t eradicate it completely.
Shifts in the healthcare sector to reduce hospital burdens and minimise patient exposure to viruses such as COVID-19 were early catalysts. With nearly 6,000 such trials underway at the end of Q3 2022, and hundreds more in the pipeline, investors are increasingly interested in the underpinning technology.
Also mentioned in the same release, was Pharmaceutical biotech Alcon admitting to conspiring with Novartis AG to bribe employees of state-owned and state-controlled hospitals and clinics in Vietnam. As a result of this case, Novartis and subsidiaries paid a sum of $345 million in criminal and regulatory penalties in 2020.
The study was conducted at Thomas Jefferson University Hospital in Philadelphia evaluated the therapy in 12 ambulatory patients. In the same time period, Warren, New Jersey-based Tevogen Bio released positive data from a trial evaluating its allogeneic T cell therapy TVGN 489, which is meant to treat high-risk COVID-19.
Citing studies comparing such products, there are no important differences between biosimilars and their branded counterpart, says Arnold Vulto, PharmD, professor of hospital pharmacy at Erasmus University, Rotterdam. These biosimilars are likely interchangeable even without a designation, he says.
For them, intravenous infusion in a hospital setting is the only option. model, download this whitepaper. By shifting injections from clinics to living rooms, these single-use, ready-to-use devices have improved the patient experience and supported treatment adherence for an array of common chronic diseases.
These advancements can also be deployed to significantly improve aftercare monitoring, reducing readmission into hospitals and dropping the overall cost of healthcare,” Ward says. AI is also being used to diagnose conditions such as cancer earlier than is generally possible. 1,2,3,4 References available on request.
This decreases the need for hospital visits and related costs, freeing up vital time and resources for doctors and nurses to treat patients most in need. Furthermore, monitoring patients when they come out of hospital helps to avoid any relapses or readmissions, effectively providing a safety net. “A
The potential scale of new infections and the questionable ability of parts of China’s hospital system to deal with the current wave of infections may lead to supply chain disruptions for the manufacture and export of active pharmaceutical ingredients (APIs) due to an adverse impact on workforce availability and delays at export hubs.
The potential scale of new infections and the questionable ability of parts of China’s hospital system to deal with the current wave of infections may lead to supply chain disruptions for the manufacture and export of active pharmaceutical ingredients (APIs) due to an adverse impact on workforce availability and delays at export hubs.
Since these adolescents are less likely to come to the hospital than babies and children, the focus needs to be on actively reaching out to those populations by using available platforms, such as school-based vaccinations. The primary target cohort is girls ages 9–14 years, which stands alone from other childhood vaccine services.
An immediate consequence of the possible legal ramifications of the bills is a shift in patient care and healthcare coverage, particularly for publicly funded hospitals.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content